• Share
  • Email
  • Embed
  • Like
  • Private Content
Kinase Inhibitors for Treating Cancer Market Forecast 2014-2024
 

Kinase Inhibitors for Treating Cancer Market Forecast 2014-2024

on

  • 243 views

For an Executive Summary of this report please contact ediz.ibrahim@visiongain.com (+44 (0)20 7549 9976) or refer to our website ...

For an Executive Summary of this report please contact ediz.ibrahim@visiongain.com (+44 (0)20 7549 9976) or refer to our website https://www.visiongain.com/Report/1275/Kinase-Inhibitors-for-Treating-Cancer-Industry-Analysis-R-D-Trends-and-World-Market-Forecasts-2014-2024

Statistics

Views

Total Views
243
Views on SlideShare
239
Embed Views
4

Actions

Likes
0
Downloads
6
Comments
0

1 Embed 4

https://twitter.com 4

Accessibility

Upload Details

Uploaded via as Adobe PDF

Usage Rights

© All Rights Reserved

Report content

Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
  • Full Name Full Name Comment goes here.
    Are you sure you want to
    Your message goes here
    Processing…
Post Comment
Edit your comment

    Kinase Inhibitors for Treating Cancer Market Forecast 2014-2024 Kinase Inhibitors for Treating Cancer Market Forecast 2014-2024 Document Transcript

    • Kinase Inhibitors for Treating Cancer: Industry Analysis, R&D Trends and World Market Forecasts 2014-2024 ©notice This material is copyright by visiongain. It is against the law to reproduce any of this material without the prior written agreement of visiongain.You cannot photocopy, fax, download to database or duplicate in any other way any of the material contained in this report. Each purchase and single copy is for personal use only.
    • www.visiongain.com Contents 1.1 Overview of the World Market for Those Medicines 1.2 Why You Should Read This Report 1.3 How This Report Delivers 1.4 Main Questions Answered by This Analysis 1.5 Who is This Study For? 1.6 Methods of Research and Analysis 1.7 Frequently Asked Questions (FAQ) 1.8 Some Associated Reports 1.9 About Visiongain 2.1 What are Protein Kinases? 2.2 Protein Kinases in Oncology 2.3 Mechanisms for Kinase Inhibition 2.4 Glossary of Terms 3.1 The Global Market for Anti-Cancer Kinase Inhibitors in 2013 3.1.1 Leading Anti-Cancer Kinase Inhibitors by Sales, 2013 3.1.2 Leading Companies in the Protein Kinase Inhibitor Market 3.2 World Protein Kinase Inhibitors for Oncology Market: Sales Forecast by Class, 2014-2024 3.2.1 Changing Market Shares by Segment 2014-2024 3.2.2 Leading Anti-Cancer Kinase Inhibitors Manufacturers, 2014-2024 3. Anti-Cancer Kinase Inhibitors: World Market 2014-2024 2. Introduction to Anti-Cancer Kinase Inhibitors 1. Report Overview
    • www.visiongain.com Contents 3.3 Bcr-Abl Inhibitors Lead the Protein Kinase Inhibitors for Oncology Market in 2013 3.3.1 Bcr-Abl Kinase Inhibitors: Drivers and Restraints 2014-2024 3.4 Imbruvica and Other Novel Kinase Inhibitors Will Eventually Dominate the Market 3.4.1 Other Kinase Inhibitors: Drivers and Restraints, 2014-2024 4.1 Regional Breakdown of the World Protein Kinase Inhibitors for Drugs Treating Cancer 4.2 World Protein Kinase Inhibitors for Oncology Market: Regional Forecast 2014-2024 4.2.1 How Will Regional Market Shares Change Through to 2024? 4.3 The US Anti-Cancer Kinase Inhibitor Market Forecast, 2014-2024 4.4 The US Market: Drivers and Restraints, 2014-2024 4.5 The EU Union Anti-Cancer Kinase Inhibitors Market Forecast, 2014-2024 4.5.1 EU Market: Drivers and Restraints 4.5.2 German Market Forecast, 2014-2024 4.5.3 French Market Forecast, 2014-2024 4.5.4 Italian Market Forecast, 2014-2024 4.5.5 UK Market Forecast, 2014-2024 4.5.6 Spanish Market Forecast, 2014-2024 4.6 The Japanese Anti-Cancer Kinase Inhibitor Market Forecast, 2014-2024 4.7 Forecasting Anti-Cancer Kinase Inhibitor Markets in Developing Countries, 2014-2024 4.7.1 Chinese Market Forecast, 2014-2024 4.7.2 Brazilian Market Forecast, 2014-2024 4.7.3 Russian Market Forecast, 2014-2024 4.7.4 Indian Market Forecast, 2014-2024 4. Leading National and Regional Markets, 2014-2024
    • www.visiongain.com Contents 5.1 Brc-Abl Inhibitors – Managed Care for Chronic Myeloid Leukaemia 5.1.1 Gleevec (imatinib) - Novartis 5.1.1.1 Historic Sales Performance 5.1.1.2 Lifecycle Management, Generic Challenges and Tasigna 5.1.1.3 Gleevec Forecast, 2014-2024 5.1.2 Sprycel (dasatanib) – Bristol-Myers Squibb 5.1.2.1 Patents and Market Exclusivity 5.1.2.2 Historic Sales Performance 5.1.2.3 Sprycel Forecast, 2014-2024 5.1.3 Tasigna (nilotinib) - Novartis 5.1.3.1 Indications and Market Exclusivity 5.1.3.2 Historic Sales Performance 5.1.3.3 Tasigna Forecast, 2014-2024 5.1.4 Bosulif (bosutinib) - Pfizer 5.1.4.1 Bosulif Forecast, 2014-2024 5.1.5 Iclusig (ponatinib) – ARIAD Pharmaceuticals 5.1.5.1 Iclusig Forecast, 2014-2024 5.2 EGFR Inhibitors 5.2.1 Tarceva (erlotinib) – Roche/Astellas 5.2.1.1 Patent Litigation and Market Exclusivity 5.2.1.2 Historic Sales Performance, 2004-2012 5.2.1.3 Tarceva Forecast, 2014-2024 5. Leading Anti-Cancer Kinase Inhibitors Products, 2014-2024
    • www.visiongain.com Contents 5.2.2 Iressa (gefitinib) - AstraZeneca 5.2.2.1 Historic Sales Performance, 2003-2012 5.2.2.2 Iressa Forecast, 2014-2024 5.2.3 Gilotrif (afatinib) - Boehringer Ingelheim 5.2.3.1 Gilotrif Forecast, 2014-2024 5.3 Angiogenesis Inhibitors 5.3.1 Nexavar (sorafenib) – Bayer/Onyx 5.3.1.1 Historic Sales Performance, 2006-2012 5.3.1.2 Nexavar Forecast, 2014-2024 5.3.2 Sutent (sunitinib) – Pfizer 5.3.2.1 Historic Sales Performance, 2006-2012 5.3.2.2 Sutent Forecast, 2014-2024 5.3.3 Votrient (pazopanib) - GSK 5.3.3.1 Historic Sales Performance, 2010-2012 5.3.3.2 Votrient Forecast, 2014-2024 5.3.4 Inlyta (axitinib) - Pfizer 5.3.4.1 Inlyta Forecast, 2014-2024 5.4 BRAF and MEK Inhibitors 5.4.1 Zelboraf (vemurafenib) – Roche/Daiichi Sankyo 5.4.1.1 Zelboraf Forecast, 2014-2024 5.4.2 Mekinist (trametinib) and Tafinlar (dabrafenib) - GSK 5.4.2.1 Mekinist Forecast, 2014-2024 5.4.2.2 Tafinlar Forecast, 2014-2024 5.5 mTOR Inhibitors
    • www.visiongain.com Contents 5.5.1 Afinitor (everolimus) - Novartis 5.5.1.1 Patents and Market Exclusivity 5.5.1.2 Historic Sales Performance 5.5.1.3 Afinitor Forecast, 2014-2024 5.5.2 Torisel (temsirolimus) – Pfizer 5.5.2.1 Torisel Forecast, 2014-2024 5.6 Other leading Anticancer Kinase Inhibitors 5.6.1 Imbruvica (ibrutinib) –J&J/Pharmacyclics 5.6.1.1 Imbruvica Forecast, 2014-2024 5.6.2 Jakafi (ruxolitinib) – Novartis/Incyte 5.6.2.1 Jakafi Forecast, 2014-2024 5.6.3 Xalkori (crizotinib) - Pfizer 5.6.3.1 Xalkori Forecast, 2014-2024 5.6.4 Cometriq (cabozantinib) – Exelixis 5.6.4.1 Cometriq Forecast, 2014-2024 5.6.5 Caprelsa (vandetanib) – AstraZeneca 5.6.5.1 Caprelsa Forecast, 2014-2024 5.6.6 Tykerb (lapatinib) - GSK 5.6.6.1 Historic Sales Performance, 2007-2012 5.6.6.2 Tykerb Forecast, 2014-2024 5.6.7 Stivarga (regorafenib) – Bayer 5.6.7.1 Stivarga Forecast, 2014-2024
    • www.visiongain.com Contents 6.1 Cyclin-Dependent Kinase 4/6 Inhibitors in Development 6.1.1 Palbociclib – Pfizer 6.1.1.1 Palbociclib Forecast, 2014-2024 6.1.2 LEE-011 – Novartis 6.1.2.1 LEE-011 Forecast, 2014-2024 6.1.3 Bemaciclib (LY2835219) – Eli Lilly 6.1.3.1 Bemaciclib Forecast, 2014-2024 6.2 Anaplastic Lymphoma Kinase (ALK) Inhibitors In Development 6.2.1 Alectinib – Roche 6.2.1.1 Alectinib Forecast, 2014-2024 6.2.2 Ceritinib (LDK378) - Novartis 6.2.2.1 Ceritinib Forecast, 2014-2024 6.2.3 AP26113 - ARIAD 6.3 Bruton’s Tyrosine Kinase and PI3K Inhibitors in Development 6.3.1 Idelalisib – Gilead 6.3.1.1 Idelalisib Forecast, 2014-2024 6.3.2 RG7601 (ABT-199) – Roche/AbbVie 6.3.2.1 ABT-199 Sales Forecast, 2014-2024 6.3.3 IPI-145 – Infinity Pharmaceuticals 6.3.3.1 IPI-145 Forecast, 2014-2024 6.3.4 Buparlisib (BKM120) – Novartis 6.3.4.1 Buparlisib Forecast, 2014-2024 6. Anti-Cancer Kinase Inhibitors: R&D Pipeline 2014-2024
    • www.visiongain.com Contents 6.3.5 ONO-4059 – Ono Pharmaceuticals 6.3.6 Copanlisib (BAY 80-6946) - Bayer 6.3.7 Pictilisib (GDC-0941) – Roche 6.3.8 BEZ235 - Novartis 6.4 MEK and BRAF Inhibitors in Development 6.4.1 Cobimetinib (GDC-0973) – Roche 6.4.1.1 Cobimetinib Forecast, 2014-2024 6.4.2 Encorafenib (LGX818) – Novartis 6.4.3 Binimetinib (MEK162) – Novartis 6.4.4 Selumetinib (AZD 6244) – AstraZeneca 6.5 Other Kinase Inhibitors in Development 6.5.1 Volasertib – Boehringer Ingelheim 6.5.1.1 Volasertib Forecast, 2014-2024 6.5.2 Neratinib (PB272) – Puma Biotechnology 6.5.3 Tivantinib (ARQ197) – Daiichi Sankyo 6.5.4 Dovotinib (TKI258) – Novartis 6.5.5 Dacomitinib – Pfizer 6.5.6 CO-1686 – Clovis Oncology 7.1 SWOT Analysis of the Protein Kinase Inhibitors for Oncology Market 7.2 Strengths 7.2.1 Oral Dosage Preferred Over Injection 7. Qualitative Analysis of the Anti-Cancer Kinase Inhibitor Market, 2014-2024
    • www.visiongain.com Contents 7.2.2 Stratifying Patients Offers Clinical and Commercial Benefits 7.2.3 Targeted Kinase Inhibitor are Generally Well Tolerated 7.2.4 A Strong Pipeline of Novel Inhibitors Will Drive Market Growth 7.3 Weaknesses 7.3.1 Small Molecule Kinase Inhibitors Will Experience Generic Competition 7.3.2 Competitor Biologics Offer Differentiated Mechanisms of Action 7.3.3 Monoclonal Antibodies are More Specific than Small Molecules 7.4 Opportunities 7.4.1 Novel Targets Identified Through Cancer Genomics 7.4.2 Combination Therapies Bring Additive Benefits 7.4.3 Commercial Success Leveraged by Clinical Benefit 7.5 Threats 7.5.1 Small Molecules Generics Are Easy to Produce 7.5.2 Individual Kinase Targets are Rapidly Becoming Crowded 7.6 STEP Analysis of the Protein Kinase Inhibitors for Oncology Market 7.7 Porter’s Five Forces Analysis of the Anti-Cancer Kinase Inhibitor Market, 2014-2024 7.7.1 Rivalry Among Competitors 7.7.2 Threat of New Entrants 7.7.3 Power of Suppliers 7.7.4 Power of Buyers 7.7.5 Threat of Substitutes 8.1 Interview with Dr Lawrence Bloch, Chief Finance and Business Officer, Infinity Pharmaceuticals, United States 8. Research Interview
    • www.visiongain.com Contents 8.1.1 Positioning a Novel Therapeutic in Blood Cancer Indications 8.1.2 Combining Therapies Offers Significant Benefit to Patients 8.1.3 Potential in Rheumatoid Arthritis and Blood Cancers 9.1 The Global Anti-Cancer Kinase Inhibitors Market to 2024 9.1.1 A Robust Pipeline of Innovative Drugs Driving Market Growth 9.2 Leading National Markets for Anti-Cancer Kinase Inhibitors to 2024 About Visiongain’s Bespoke Research Service Associated Visiongain Reports Report Sales Order Form About Visiongain Report Evaluation Form Appendices 9. Conclusions
    • www.visiongain.com Page 75 Kinase Inhibitors for Treating Cancer: Industry Analysis, R&D Trends and World Market Forecasts 2014-2024 release of novel kinase inhibitor classes such as the CDK4/6 and PI3K inhibitors, along with stratified treatments in existing inhibitor classes. However, significant downward pressure on the market will exist from the flood of generic inhibitors set to reach the market during that time. Table 4.10 Forecast Italian Anti-Cancer Kinase Inhibitor Market: Market Size ($bn), Annual Growth (%), CAGR (%), 2013-2024 2013 2014 2015 2016 2017 2018 Italy ($bn) 0.82 0.93 1.00 1.05 1.11 1.24 Annual Growth (%) 14.3 7.3 4.9 5.5 12.0 CAGR (%) 8.7 2019 2020 2021 2022 2023 2024 Italy ($bn) 1.30 1.30 1.25 1.34 1.36 1.37 Annual Growth (%) 5.0 -0.1 -3.7 7.4 1.1 1.1 CAGR (%) 1.7 Figure 4.12 Forecast Italian Anti-Cancer Kinase Inhibitor Market: Market Size ($bn), 2013-2024 4.4.5 UK Market Forecast, 2014-2024 The UK forms one of the most important national markets for pharmaceuticals, despite its relatively small population. Approval for medicinal use in the UK is assessed by NICE using cost- effectiveness measurement. Decisions handed down by NICE are often used as a benchmark in 0.00 0.20 0.40 0.60 0.80 1.00 1.20 1.40 1.60 2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 Marketsize($bn) Year Source: visiongain 2014 CAGRs for periods 2013-2018 and 2018-2024. Source: visiongain 2014
    • www.visiongain.com Page 168 Kinase Inhibitors for Treating Cancer: Industry Analysis, R&D Trends and World Market Forecasts 2014-2024 benefit in patients with NSCLC, leading to an initial rejection of early use by the FDA. The drug is far more effective in patients with mutated, over-active forms of EGFR. In these patients Tarceva is highly effective and in 2013 the FDA approved its use as a first line therapy for NSCLC patients who have EGFR mutation status confirmed by DNA tumour testing. Resistant to first-generation EGFR inhibitors has been attributed to the development of a point mutation at position 790 in the EGFR gene. This mutation substitutes a small polar threonine reside for a large non-polar methionine residue. The second-generation of EGFR inhibitors have been designed to target this mutation as well allowing the drug to be used before or after resistance develops. Drugs specifically designed to target and provide clinical benefit to a subset of identifiable patients are very commercially attractive. Manufacturers will often be able to circumvent cost-effectiveness measurements that would otherwise limit reimbursement and ensure high treatment prices. Highly specific therapies can also reduce off-target adverse effects, increasing their clinical potential. In the case of EGFR inhibitors, sparing the wild-type receptor reduces the incidence of skin rash which is caused by unwanted inhibitor of normal receptor activity. Cancer genomics will continue to provide highly specific targets for novel stratification of patient groups. Visiongain believes this stratification of patients will provide substantial benefit to developers, reducing the cost of clinical development and enhancing the commercial potential of treatments. 7.2.3 Targeted Kinase Inhibitor are Generally Well Tolerated Standard chemotherapy treatments for cancer involve the use of non-selective cytotoxic anti- neoplastic drugs administered intravenously. These therapies act by killing all cells that divide rapidly, targeting both cancerous and healthy and causing significant adverse treatment effects. Novel targeted kinase inhibitors are designed to suppress cancerous cell growth without the indiscriminate killing of healthy cells. This leads to better tolerance of targeted therapeutics in general when compared to standard cytotoxic drugs. However, there are still adverse treatment effects reportedly associated with kinase inhibitors both from widespread inhibition of kinase activity and unwanted off-target effects. For example the first generation EGFR inhibitors apparently display marked cutaneous toxicity due to inhibition of normal wild-type EGFR function in differentiating skin cells. The ability to specifically inhibit over-active oncogenic kinases will allow further reduction in unwanted side-effect and promote the use of targeted kinase inhibitors over generalised cytotoxic chemotherapy. 7.2.4 A Strong Pipeline of Novel Inhibitors Will Drive Market Growth Protein kinases are one of the leading targets in drug development with over 600 products currently in development. Candidates which demonstrate significant clinical efficacy at early
    • www.visiongain.com Page 178 Kinase Inhibitors for Treating Cancer: Industry Analysis, R&D Trends and World Market Forecasts 2014-2024 145 could be an important treatment option for patients who stop responding, or do not respond, to Imbruvica. 8.1.2 Combining Therapies Offers Significant Benefit to Patients visiongain: Are there any plans for a potential combination therapeutic further down the line? LB: Our vision is that best route to approval is as a monotherapy, but we believe that the best benefit for patients may be through a two stage process. First combining IPI-145 with the standard of care such as Rituxan, and we have a clinical trial planned for the second half of 2014. The next stage is combining IPI-145 with other targeted therapies, with the aspiration to achieve minimal residual disease (MRD) negativity. visiongain: Which other targeted therapies do you think would work as a combination? LB: We are doing a very robust pre-clinical evaluation to answer that question as there are some drugs that would be intuitive combinations and others which you wouldn’t predict to be synergistic. For example at the American Society for Hematology (ASH) meeting in December 2013, we presented data on the synergistic benefit of IPI-145 with Imbruvica in diffuse large B-cell (DLBCL) cell lines. We think this combination has empirical basis for synergy because the drugs have parallel but non-overlapping mechanisms. So far the pre-clinical data indicates that the synergist effect may be greater than expected for combining these treatments, more like one plus one equals three. When you think about this compared to HIV treatment as an analogy. It was standard practice to have an HIV monotherapy in the 1980s, but now it is the standard of care to provide multiple combinations therapies. In fact, currently it wouldn’t be advisable to prescribe an HIV monotherapy as the virus can mutate and become resistant to treatment. This is also the case with NHL and CLL where the cancer can become resistant to treatment or potential become an even more aggressive from. We think hitting the cancer early with multiple therapies will prevent mutations from developing and will provide significant benefits for patients. visiongain: Combining novel treatments is going to become hugely expensive for payers, how is this going to be addressed? LB: That’s a fair question, but this is the same question that occurred with HIV triple therapies. Ultimately, the triple therapy was so much more efficacious than monotherapy there was a substantial benefit for patients. But also the developers of the single therapies had to come together to make a way for it be cost-effective for third party payers.